ClinicalTrials.gg
WithdrawnNCT07402330Updated Nov 2, 2026

Pharmacokinetic Study of DA-020

An Early Phase 1 interventional study of DA-020 (0.1%) and DA-020 (0.2%) in Chemotherapy Induced Alopecia and Chemotherapy Side Effects, sponsored by Applied Biology, Inc.. Withdrawn at 2 sites in 2 countries. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Applied Biology, Inc. · Early Phase 1, Interventional, and Treatment

Why this study was withdrawn
Change of protocol moved to new study
Updated Nov 2, 2026Now WithdrawnStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..

Started
2026
with 2 others
Phase 1
2 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2026, is one of 2 in phase 1, and was the 12th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Alopecia by Applied Biology, Inc., or all of them as a file.
02

Study summary

Pharmacokinetic Study of DA-020

Read the detailed description

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of DA-020

03

Conditions studied

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Browse trials for

Keywords

  • Chemotherapy Induced Alopecia
  • Chemotherapy Alopecia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy females, age 18-55
  • : 18-30 kg/m²
  • Fitzpatrick Skin Types I-IV (to standardize absorption risk)
  • Scalp free from irritation, dermatologic disease, or damage
  • Able to refrain from using other topical scalp products

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular disease, hypertension, or arrhythmia
  • Scalp infections, wounds, or significant hair loss
  • Recent use of medications that interfere with CYP enzymes or adrenergic systems
  • Known sensitivity to phenylephrine or ethanol
  • Positive drug screen or abnormal at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    DA-020 (0.1%)

    Topical Oxymetazoline 0.1% - 7mL

    Drug: DA-020 (0.1%)

  • Experimental
    DA-020 (0.2%)

    Topical Oxymetazoline 0.2% - 7mL

    Drug: DA-020 (0.2%)

  • Experimental
    DA-020 (0.5%)

    Topical Oxymetazoline 0.5% - 7mL

    Drug: DA-020 (0.5%)

Interventions

  • DrugDA-020 (0.1%)

    DA-020 (0.1%)

  • DrugDA-020 (0.2%)

    DA-020 (0.2%)

  • DrugDA-020 (0.5%)

    DA-020 (0.5%)

06

What researchers measure

Primary outcomes

  1. Concentration of DA-020 in Serum

    Determine the amount of Oxymetazoline in serum after 1 time scalp application

    Time frame: Hours [0, 1, 2, 4, 8, 12, 24]

Secondary outcomes

  1. Safety and tolerability of DA-020

    Determine blood pressure following a single application of DA-020

    Time frame: Hours [0, 1, 2, 4, 8, 12, 24]

07

Study locations

2 sites
  • Hospital Samel
    Manaus, Brazil
  • University of Rome ("G. Marconi")
    Rome, Italy
08

References and documents

Publications

  • Fahl WE. Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors. Arch Dermatol Res. 2016 Dec;308(10):751-757. doi: 10.1007/s00403-016-1691-2. Epub 2016 Oct 4. PubMed 27704205 ↗
  • Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015 Jan 1;136(1):195-203. doi: 10.1002/ijc.28961. Epub 2014 May 16. PubMed 24811525 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Oct 2026, 6 months.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 11, 2026
StartActual
Apr 16, 2026
Primary completionActual
Oct 19, 2026
CompletionActual
Oct 30, 2026was Nov 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Change of protocol moved to new study
changed Nov 2, 2026
Study completion
Nov 30, 2026→Oct 30, 2026 (actual)
Nov 2, 2026
Enrollment
60 (estimated)→0 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Withdrawn
    Why stopped Change of protocol moved to new study
    Study completion Nov 30, 2026→Oct 30, 2026 (now actual)
    Enrollment 60 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07402330
Collaborators
Daniel Alain, Inc., Follea International Limited
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Apr 16, 2026
Primary completion
Oct 19, 2026
Completion
Oct 30, 2026
Last update
Nov 2, 2026

Study contacts

Andy Goren, MD
study director · University of Rome G. Marconi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion